Status:
UNKNOWN
Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer
Lead Sponsor:
Ahmed A. H. Abdellatif
Conditions:
Colon Cancer
Colo-rectal Cancer
Eligibility:
All Genders
20-60 years
Phase:
PHASE1
Brief Summary
Due to the great toxicity of chemotherapeutic drugs to both the healthy and cancerous area, the efficient targeting could be of great benefit for a patient with advanced or metastatic tumors. Colorect...
Detailed Description
The investigator's aim is to deliver polymeric nanoparticles loaded with anti-cancer drug Cetuximab and decorated with somatostatin analogue in the form of oral polymeric nanoparticles, which can rele...
Eligibility Criteria
Inclusion
- Clinical diagnosis of colon cancer
- Follow up and collect data for a local and systemic activity of cetuximab
- The systemic oral capsule of cetuximab be also given to enhance the activity as an anti-cancer activities
Exclusion
- Peptic ulcer
- Stomach disease
- Colon cancer
Key Trial Info
Start Date :
February 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 11 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03774680
Start Date
February 1 2020
End Date
January 11 2021
Last Update
October 10 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut Clinic
Asyut, Egypt, 71526
2
Buraidah Clinic
Buraidah, Al Qassim, Saudi Arabia, 51171
3
Faculty of Pharmacy
Buraidah, Al-Qassim Region, Saudi Arabia, 51452
4
Pharmaceutics dept., Faculty of Pharmacy, Qassim University
Buraidah, Al-Qassim Region, Saudi Arabia, 51452